Nav: Home

Researchers zero in on potential therapeutic target for diabetes, associated diseases

December 19, 2018

COLLEGE STATION - A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential therapeutic target for its prevention.

The study can be found online in the November edition of the diabetes journal of the American Diabetes Association at http://diabetes.diabetesjournals.org/content/67/11/2167 or PubMed.gov at https://www.ncbi.nlm.nih.gov/pubmed/30201683.

"Glucagon and insulin are the most important pancreatic hormones in target tissues, such as the liver, in control of proper glucose levels in response to food intake," explained Dr. Shaodong Guo, Texas A&M AgriLife Research scientist in the department of nutrition and food science at Texas A&M University, College Station.

Guo was primary investigator and corresponding author for the study, which involved several other researchers from the department. Additional participation in the study came from the department of endocrinology at Third Military Medical University, Chongqing, China; the division of endocrinology, department of medicine, Johns Hopkins University, Baltimore, Maryland; and the department of chemistry, Cleveland State University, Cleveland, Ohio.

During fasting, Guo said, glucagon is secreted from pancreatic a-cells to elevate blood glucose, protecting the body from hypoglycemia. Glucagon also has been tied to the development of diabetic hyperglycemia, mainly through enhancing hepatic glucose production, or HGP.

Transcription factor Foxo1, a protein that plays an important role in regulating the expression of genes, promotes HGP through increasing expression of genes encoding the rate-limiting enzymes responsible for glucose production, he said.

"Glucagon exerts its function through binding to a G-protein-coupled receptor or GCGR," Guo explained. "When the receptor binds with glucagon it stimulates the cell membrane, which in turn activates protein kinase A, or PKA, signaling for metabolic enzymes or gene expression to increase blood glucose."

Guo said an excess blood glucagon level is present in animals and humans with diabetes, stimulating excessive HGP and contributing to diabetic hyperglycemia.

"Disruption of proper hepatic glucose production serves as a major underlying mechanism for the development of Type 2 diabetes," he said. "The pancreatic hormone glucagon increases HGP and insulin decreases it. Together, they control blood glucose homeostasis."

Guo said glucose production is suppressed by insulin involved in the gene transcriptional regulation in the nucleus of liver cells, and Foxo1 is an important component of insulin-signaling cascades that regulate cellular growth, differentiation and metabolism.

"The purpose of this study was to learn what role Foxo1 plays in how glucagon regulates HGP," he said. "We investigated the molecular and physiological mechanism of Foxo1 regulation through phosphorylation with the aim of better understanding the fundamentals of blood glucose homeostasis and the pathogenesis of diabetes."

Phosphorylation, the attachment of a phosphoryl group, is important for protein function as this alteration activates or deactivates almost half of the body's enzymes, regulating their function.

To establish how this Foxo1 phosphorylation would work in an animal model, the researchers used CRISPR/CAS9 technology in the generation of Foxo1 'knock-in' mice to use in their investigation.

"Foxo1 is stabilized in the liver of fasting mice when insulin is decreased and glucagon is increased in the blood circulation," he said. "Stimulating the GCGR results in the activation of adenylate cyclase, an enzyme playing key regulatory roles in essentially all cells, and produces increased levels of intracellular PKA."

Guo said the study showed hepatic Foxo1 deletion in the mice significantly reduced hepatic glucose production and blood glucose.

"This result, along with what we learned from some the previous research done in conjunction with the department, showed we had identified a novel molecular, cellular and physiological mechanism by which Foxo1 mediates glucagon signaling via phosphorylation to control hepatic gluconeogenesis and blood glucose," he said.

Guo said this study further demonstrated that Foxo1 is a mediator of multiple signaling cascades and integrates different hormones and intracellular protein kinases into the programming that controls insulin sensitivity, HGP and blood glucose.

"A high glucagon level is present in both Type 1 and Type 2 diabetes, and Foxo1 plays a key role in the fundamental mechanism leading to excess liver gluconeogenesis and resulting in diabetic hyperglycemia," Guo said. "This suggests glucagon-mediated HGP could be a significant potential therapeutic intervention for the control and possible prevention of diabetes."
-end-


Texas A&M AgriLife Communications

Related Diabetes Articles:

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.
Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.
Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).
Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.
People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.
Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.
New oral diabetes drug shows promise in phase 3 trial for patients with type 1 diabetes
A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes.
Can continuous glucose monitoring improve diabetes control in patients with type 1 diabetes who inject insulin
Two studies in the Jan. 24/31 issue of JAMA find that use of a sensor implanted under the skin that continuously monitors glucose levels resulted in improved levels in patients with type 1 diabetes who inject insulin multiple times a day, compared to conventional treatment.
Complications of type 2 diabetes affect quality of life, care can lead to diabetes burnout
T2D Lifestyle, a national survey by Health Union of more than 400 individuals experiencing type 2 diabetes (T2D), reveals that patients not only struggle with commonly understood complications, but also numerous lesser known ones that people do not associate with diabetes.
A better way to predict diabetes
An international team of researchers has discovered a simple, accurate new way to predict which women with gestational diabetes will develop type 2 diabetes after delivery.
More Diabetes News and Diabetes Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Clint Smith
The killing of George Floyd by a police officer has sparked massive protests nationwide. This hour, writer and scholar Clint Smith reflects on this moment, through conversation, letters, and poetry.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.